NDA 200327 · Abbvie
Teflaro
Ceftaroline Fosamil · Intravenous
NovelLast checked: Nov 19, 2026Latest source record: Dec 2, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Oct 29, 2010
Approved uses
6
Original approval plus efficacy supplements
Registered trials
47
13 Phase 3, 2 recruiting
FAERS reports
839
679 serious, 154 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 20, 2024.
1. INDICATIONS AND USAGE Teflaro is a cephalosporin antibacterial indicated in adult and pediatric patients for the treatment of the following infection caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections (ABSSSI) in adult and pediatric patients (at least 34 weeks gestational age and 12 days postnatal age) ( 1.1 ) Community-acquired bacterial pneumonia (CABP) in adult and pediatric patients 2 months of age and older ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Teflaro and other antibacterial drugs, Teflaro should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) 1.1 Acute Bacterial Skin and Skin Structure Infections Teflaro is indicated in adult and pediatric patients (at least 34 weeks gestational age and 12 days postnatal age) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes , Streptococcus agalactiae , Escherichia coli , Klebsiella pneumoniae , and Klebsiella oxytoca [see Dosage and Administration ( 2.2 ) and Use in Specific Populations ( 8.4 )] . 1.2 Community-Acquired Bacterial Pneumonia Teflaro is indicated in adult and pediatric patients 2 months of age and older for the treatment of community-acquired bacterial pneumonia (CABP) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: Streptococcus pneumoniae (including cases with concurrent bacteremia), Staphylococcus aureus (methicillin-susceptible isolates only), Haemophilus influenzae,...
Mechanism: Ceftaroline is a cephalosporin antibacterial drug [ see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 13, 2019 Supplement 22 · Efficacy LetterLabelPediatric Medical Review
- May 27, 2016 Supplement 16 · Efficacy · priority review LabelPediatric Medical ReviewPediatric CDTL Review
- May 27, 2016 Supplement 17 · Efficacy · priority review Pediatric Medical ReviewPediatric CDTL ReviewPediatric Clinical Pharmacology Review
- Aug 31, 2015 Supplement 14 · Efficacy LabelLetter
- Aug 31, 2015 Supplement 13 · Efficacy Letter
- Oct 29, 2010 Original approval · Type 1 - New Molecular Entity NovelLabelReviewSummary Review
2 products under this application
- TEFLARO · CEFTAROLINE FOSAMIL 600MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
- TEFLARO · CEFTAROLINE FOSAMIL 400MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Ceftaroline Fosamil" as an intervention, any sponsor and status, largest first.
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Combination Antibiotic Therapy for Staphylococcus Aureus BacteremiaPivotal-lookingRecruiting
Intermountain Health Care, Inc.Academic, hospital or other
NCT07376889 · 2,096 participants (planned) · Start Feb 1, 2026 · Primary completion Jan 2029
Drug: Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Brighton, Colorado; Denver, Colorado; Grand Junction, Colorado · 13 sites in all
- A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in AsiaPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01371838 · 848 participants · Start Dec 2011 · Primary completion May 2013
Drug: Ceftaroline; Ceftriaxone · For: Community-Acquired Bacterial Pneumonia; Lung Infection of Individual Not Recently Hospitalized
Sites: Beijing, China; Chengdu, China; Guangzhou, China · 43 sites in all
- Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin InfectionsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01499277 · 802 participants · Start May 2012 · Primary completion Jun 2014
Drug: Ceftaroline fosamil; Vancomycin and 1 more · For: Complicated Skin and Soft Tissue Infection
Sites: Chula Vista, California; Orlando, Florida; West Palm Beach, Florida · 91 sites in all
- Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin InfectionsPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00424190 · 698 participants · Start Feb 2007 · Primary completion Nov 2007
Drug: IV Vancomycin plus IV Aztreonam; Ceftaroline · For: Bacterial Infections
Sites: Dothan, Alabama; Long Beach, California; Los Angeles, California · 52 sites in all
- Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin InfectionsPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00423657 · 680 participants · Start Mar 2007 · Primary completion Dec 2007
Drug: ceftaroline; vancomycin plus aztreonam and 1 more · For: Bacterial Infections
Sites: Buena Park, California; Hawaiian Gardens, California; Los Angeles, California · 54 sites in all
- Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired PneumoniaPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00509106 · 622 participants · Start Jul 2007 · Primary completion Aug 2008
Drug: Ceftaroline fosamil for Injection; Ceftriaxone and 1 more · For: Bacterial Pneumonia
Sites: Durham, North Carolina; Autonoma, Argentina; Mar del Plata, Argentina · 134 sites in all
- Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired PneumoniaPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00621504 · 606 participants · Start Jan 2008 · Primary completion Dec 2008
Drug: Ceftaroline fosamil for Injection; IV Ceftriaxone and 2 more · For: Bacterial Pneumonia
Sites: Los Angeles, California; Pasadena, California; Sacramento, California · 168 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use141
- neutropenia77
- drug ineffective64
- acute kidney injury52
- death48
- rash46
- agranulocytosis40
- thrombocytopenia37
- pyrexia34
- drug reaction with eosinophilia and systemic symptoms33
- renal failure31
- pruritus29
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 15 |
| 2012 | 29 |
| 2013 | 53 |
| 2014 | 71 |
| 2015 | 37 |
| 2016 | 49 |
| 2017 | 30 |
| 2018 | 45 |
| 2019 | 53 |
| 2020 | 42 |
| 2021 | 59 |
| 2022 | 34 |
| 2023 | 62 |
| 2024 | 85 |
| 2025 | 78 |
| 2026 | 97 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Teflaro (Ceftaroline Fosamil Acetate)
2024 spending
$12.5M
Beneficiaries
929
4,467 claims
Per beneficiary
$13,509
$45.07 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $11,106,086 |
| 2021 | $10,145,910 |
| 2022 | $11,329,226 |
| 2023 | $11,267,093 |
| 2024 | $12,549,725 |
Part B: Teflaro (Ceftaroline Fosamil Acetate) · HCPCS J0712
2024 spending
$231K
Beneficiaries
115
592 claims
Per beneficiary
$2,008
2024 ASP limit $3.91 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $526,180 |
| 2021 | $474,880 |
| 2022 | $369,311 |
| 2023 | $332,769 |
| 2024 | $230,930 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and effectiveness of ceftaroline fosamil in children: a systematic review and meta-analysis.
Rosanova MT, Sberna N, Lede R · Arch Argent Pediatr 2019 · Comparative Study, Meta-Analysis
- Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis.
Sotgiu G, Aliberti S, Gramegna A, et al. · Respir Res 2018 · Meta-Analysis, Systematic Review
- Comparative effectiveness and safety of six antibiotics in treating MRSA infections: A network meta-analysis.
Ju G, Zhang Y, Ye C, et al. · Int J Infect Dis 2024 · Comparative Study, Network Meta-Analysis
- Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: a systematic review.
El Hajj MS, Turgeon RD, Wilby KJ · Int J Clin Pharm 2017 · Systematic Review
- Off-label use of ceftaroline fosamil: A systematic review.
Pani A, Colombo F, Agnelli F, et al. · Int J Antimicrob Agents 2019 · Systematic Review
- Pharmacokinetics of single-dose ceftaroline fosamil in children with cystic fibrosis.
Le J, Bradley JS, Hingtgen S, et al. · Pediatr Pulmonol 2017 · Clinical Trial, Phase I
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.